Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUBILEE: Janumet and Lantus in T2DM
NCT01269996Phase 4Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2011
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sitagliptin + metformin and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Treatment efficacy (HbA1c control) at 1 year. Started May 2011; status: completed.
02
Drugs
sitagliptin + metformininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01269996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01269996.